Smilez, I completely agree with you on this.
As per your post in Sept 2013, the patent for the Magnotech device , shows that multiple types of potential royalties were accounted for with every test, so they are patenting the idea that they expect many different parties to potentially be involved with this device.
They cannot be experts in everything, so may have Anteo as a royalty for our multiplexing component, and a specialist diagnostic test company that has developed a test for HIV for example on the same test.
They may even find themselves with more than that on some tests with the inclusion of a DNA specialist etc.
They definitely aren't planning on going it alone.
Smilez Hotcopper post 12285720
IN VITRO DIAGNOSTIC TESTING INCLUDING AUTOMATED BROKERING OF ROYALTY PAYMENTS FOR PROPRIETARY TESTS
"A method comprises: recording an electronic record of diagnostic events including the performing of in-vitro diagnostic tests; during the recording, identifying the performing of a licensed in-vitro diagnostic test for which license information is stored in a licenses database; and computing license compensation due to a licensor for the performing of the licensed in-vitro diagnostic test based on royalty calculation information stored in the licenses database"
(20min delay)